SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-017147
Filing Date
2024-04-30
Accepted
2024-04-30 07:45:36
Documents
14
Period of Report
2024-04-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 51394
2 ex99-1.htm EX-99.1 28524
  Complete submission text file 0001493152-24-017147.txt   265513

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE dare-20240429.xsd EX-101.SCH 3033
4 XBRL LABEL FILE dare-20240429_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE dare-20240429_pre.xml EX-101.PRE 22371
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3658
Mailing Address 3655 NOBEL DRIVE SUITE 260 SAN DIEGO CA 92122
Business Address 3655 NOBEL DRIVE SUITE 260 SAN DIEGO CA 92122 858-926-7655
Dare Bioscience, Inc. (Filer) CIK: 0001401914 (see all company filings)

IRS No.: 204139823 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36395 | Film No.: 24894069
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)